Head & neck · 2026
Glypican-1-Targeted Antibody-Drug Conjugate Exhibits Antitumor Effects Against Oral Squamous Cell Carcinoma.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Obata Kengo, Serada Satoshi, Suzuki Yuji, Tuchida Kodai, Miyaguchi Jun, Funajima Eiji, Yamada Hiroyuki, Naka Tetsuji
Аннотация
BACKGROUND: Oral squamous cell carcinoma (OSCC) is a major health concern with limited therapeutic options. Glypican-1 (GPC1), a heparan sulphate proteoglycan, has been implicated in several malignancies; however, its therapeutic role in OSCC remains elusive. This study investigated the potential of a novel glypican-1 antibody-drug conjugate (GPC1-ADC) conjugated with monomethyl auristatin E as a therapeutic strategy for OSCC.
METHODS: GPC1 expression in OSCC tissues was examined by immunohistochemistry using tissue microarrays and by western blotting in OSCC cell lines. The cytotoxicity of GPC1-ADC was assessed using in vitro viability assays, and its effects on the cell cycle and apoptosis were analyzed using flow cytometry and caspase-3/7 activity assays. In vivo antitumor efficacy was evaluated using OSCC cell line-derived and patient-derived xenograft (PDX) mouse models.
RESULTS: High GPC1 expression was observed in 78% (39/50) of OSCC cases, whereas normal oral tissues showed no detectable expression. Western blotting confirmed GPC1 protein expression in all the OSCC cell lines tested. GPC1-ADC markedly reduced cell viability in a dose-dependent manner (IC550 = 0.053-0.117 nM), induced G2/M-phase arrest, and activated caspase-3/7, indicating apoptosis. In vivo, high-dose GPC1-ADC markedly inhibited tumor growth in both xenograft and PDX models compared with control treatments, without causing weight loss.
CONCLUSION: GPC1-ADC demonstrated potent and specific antitumor activity against GPC1-expressing OSCC in vitro and in vivo. These findings suggest that GPC1-ADC is a promising therapeutic candidate for OSCC and may provide a basis for new treatment strategies; however, further preclinical and clinical evaluation is warranted.
METHODS: GPC1 expression in OSCC tissues was examined by immunohistochemistry using tissue microarrays and by western blotting in OSCC cell lines. The cytotoxicity of GPC1-ADC was assessed using in vitro viability assays, and its effects on the cell cycle and apoptosis were analyzed using flow cytometry and caspase-3/7 activity assays. In vivo antitumor efficacy was evaluated using OSCC cell line-derived and patient-derived xenograft (PDX) mouse models.
RESULTS: High GPC1 expression was observed in 78% (39/50) of OSCC cases, whereas normal oral tissues showed no detectable expression. Western blotting confirmed GPC1 protein expression in all the OSCC cell lines tested. GPC1-ADC markedly reduced cell viability in a dose-dependent manner (IC550 = 0.053-0.117 nM), induced G2/M-phase arrest, and activated caspase-3/7, indicating apoptosis. In vivo, high-dose GPC1-ADC markedly inhibited tumor growth in both xenograft and PDX models compared with control treatments, without causing weight loss.
CONCLUSION: GPC1-ADC demonstrated potent and specific antitumor activity against GPC1-expressing OSCC in vitro and in vivo. These findings suggest that GPC1-ADC is a promising therapeutic candidate for OSCC and may provide a basis for new treatment strategies; however, further preclinical and clinical evaluation is warranted.